daewoong gliatamin cdmo
Scope
Date
~
-
Bio & Pharma
Daewoong Pharma, UK firm to jointly develop autoimmune disease drug
South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday that it has signed a cooperation agreement with Sygnature Discovery, a British ne...
Apr 18, 2023 (Gmt+09:00)
-
Pre-IPOs
SK Pharmteco again seeks $382 mn in pre-IPO funding
SK Pharmteco Co., a contract development and manufacturing organization (CDMO), is eyeing pre-initial public offering funding again after it dropped...
Mar 21, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Biologics to invest $1.5 bn for 5th CDMO factory
Samsung Biologics Co. is slated to inject 2 trillion won ($1.5 billion) to build its fifth plant in South Korea. It will be a fast follow-up investm...
Mar 16, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's Prestige Biologics attracts $59 mn overseas investment
Prestige Biologics Co., a South Korean biopharmaceutical contract development and manufacturing organization (CDMO) company, announced on Tuesday th...
Mar 15, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong wins approval for GERD treatment Fexuclu in Chile
South Korean pharmaceutical company Daewoong Pharmaceutical announced on Tuesday that it has received marketing authorization from Chile's National ...
Mar 14, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong’s Nabota expands into Germany, Austria
South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday it had launched its botulinum toxin product Nabota in Germany and Austria through i...
Mar 02, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma's Fexuclue safe to use with aspirin: Clinical trials
Daewoong Pharmaceutical Co., a leading South Korean pharmaceutical company, has announced the successful completion of phase 1 clinical trials for...
Feb 28, 2023 (Gmt+09:00)
-
Bio & Pharma
Korea's Daewoong to export diabetes drug Envlo to Brazil, Mexico
South Korea’s Daewoong Pharmaceutical Co. said on Feb. 24 it is set to embark on global sales of Envlo, a new drug for diabetes, by exportin...
Feb 24, 2023 (Gmt+09:00)
-
Bio & Pharma
Korean court rules Daewoong poached Medytox’s botox strain
A South Korean court on Friday ruled in favor of Medytox Inc. in a civil lawsuit against its crosstown rival Daewoong Pharmaceutical Co. over the so...
Feb 10, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma wins permission from Singapore for Nabota
South Korea's drug development company Daewoong Pharmaceutical said on Thursday that it received on Jan. 20 product approval for its botulinum toxin...
Feb 10, 2023 (Gmt+09:00)
-
Bio & Pharma
Medytox to sell off 2.2 mn shares of Daewoong's American partner Evolus
Medytox Inc. said in a regulatory filing on Wednesday that it is selling off approximately 2.19 million shares of Evolus, Daewoong Pharmaceutical's ...
Feb 08, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong receives approval for its GERD drug Fexuclue in Ecuador
Daewoong Pharmaceutical said Friday that it has obtained marketing authorization from Ecuador's National Agency for Health Regulation, Control and S...
Feb 06, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma's botulinum toxin Nabota proves long-lasting effect
Daewoong Pharmaceutical said on Friday that a high-dose administration of botulinum toxin Nabota (US brand name: Jeuveau) to patients with frown wri...
Feb 03, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's Daewoong Pharmaceutical to export tech to British company
South Korea's Daewoong Pharmaceutical has licensed a new drug candidate for idiopathic pulmonary fibrosis (IPF) to CS Pharmaceuticals (CSP) of the U...
Feb 01, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea, Japan compete in gastroesophageal reflux drug market
South Korea is battling Japan again, this time on the global market to treat gastroesophageal reflux disease (GERD). South Korea's pharmaceutical pr...
Jan 27, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma's botulinum toxin Nabota wins approval from Australia
Daewoong Pharmaceutical said on Wednesday that its botulinum toxin formulation Nabota (overseas brand name: Nuceiva) won approval in Australia on Ja...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong accelerates investment in CDMO business
Daewoong, the holding company of South Korea's pharmaceutical-oriented Daewoong Group, is speeding up its pace to beef up its contract development a...
Jan 18, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong, Onchorus to undertake research on mRNA anticancer drugs
Daewoong Pharmaceutical said on Thursday that it has signed a joint R&D and commercialization agreement with America's biopharmaceutical venture...
Jan 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma, Neurolive to jointly develop new antidepressant drug
South Korea's drug company Daewoong Pharmaceutical said on Wednesday that it has signed an agreement with biopharmaceutical venture Neurorive to joi...
Dec 28, 2022 (Gmt+09:00)
-
Bio & Pharma
Daewoong submits new drug applications for Fexuclue in 10 countries
South Korea's leading drug company Daewoong Pharmaceutical is accelerating its global expansion efforts for its 34th domestically developed drug Fex...
Dec 14, 2022 (Gmt+09:00)
-
Bio & Pharma
Korea approves Daewoong Pharmaceutical's diabetes drug
DAEWOONG PHARMACEUTICAL has received domestic approval for its diabetes drug Envlo with the active ingredient enavogliflozin, the second straight ye...
Dec 02, 2022 (Gmt+09:00)
-
Bio & Pharma
Medipost, OmniaBio to enhance cooperation for CDMO business
South Korea's stem-cell therapy company Medipost announced on Thursday that its Canadian affiliate OmniaBio made a two-day visit to South Korea on N...
Dec 01, 2022 (Gmt+09:00)
-
Bio & Pharma
Samsung Biologics in CDO deal talks with global pharma firm
FRANKFURT – Samsung Biologics Co., the world’s largest contract drugmaker, is in talks to develop medicines for a global pharmaceutical ...
Nov 07, 2022 (Gmt+09:00)
-
Bio & Pharma
Medipost to expand CDMO business with 10 new clean rooms in Korea
Medipost Co, a South Korean biotechnology company, is expanding its cell and gene therapy contract development and manufacturing organization (CDMO)...
Oct 18, 2022 (Gmt+09:00)
-
Bio & Pharma
Samsung Biologics opens the world's largest CDMO factory
South Korea’s Samsung Biologics Co.’s new biopharmaceuticals plant launched operations on Tuesday, a move expected to widen the gap betw...
Oct 11, 2022 (Gmt+09:00)
-
Bio & Pharma
K-bio firms embrace gene therapy CDMO as Samsung looks the other way
South Korea’s major biopharmaceutical companies are rapidly embracing the cell and gene therapy business under a contract drug-making mechanis...
Aug 05, 2022 (Gmt+09:00)
-
Bio & Pharma
Samsung Biologics to double CDMO capacity with new plants worth $5.3 bn
Samsung Biologics Co., the world’s largest contract drugmaker, plans to double its manufacturing capacity by building four additional plants w...
Jul 18, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion, Samsung Biologics eye record-high annual sales
South Korea’s two major biopharmaceutical companies, Celltrion Inc. and Samsung Biologics Co., are respectively expecting more than 2 trillion...
Jul 08, 2022 (Gmt+09:00)
-
Bio & Pharma
Medipost acquires Canada’s OmniaBio for CDMO business
Medipost Co., a South Korean biotechnology company, has acquired a 39.6% stake in OmniaBio Inc., a Canada-based cell and gene therapy contract devel...
May 31, 2022 (Gmt+09:00)
-
Bio & Pharma
Daewoong's Nabota approved for sale in Saudi Arabia, Ukraine
South Korea’s Daewoong Pharmaceutical Co. has obtained approval for the sale of its botulinum toxin product, Nabota, in Saudi Arabia and Ukrai...
May 19, 2022 (Gmt+09:00)